drugset / Trial / NCT02180464

A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis

NCT02180464 ↗

Phase 2 Completed 40 enrolled Almirall, S.A.
RandomizedSingle-groupTriple-blindTreatment

Summary

Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).

Timeline

Start
2014-06
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LAS41004 Unknown — Topical

Indications